GSK Vows To Eradicate Lymphatic Filariasis By 2020
This article was originally published in PharmAsia News
MUMBAI - GlaxoSmithKline is taking steps to eradicate lymphatic filariasis, a crippling tropical disease that is estimated to cost the Indian economy $840 million each year. GSK plans to invest nearly $340,000 in its Nashik, India facility and double its current global capacity for the production of albendazole
You may also be interested in...
GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 1 of 2)
GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).